3Fang J, Shing Y ,Wiederschain D ,et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA,2000,97(8) :3 884.
4Mitsiades N, Poulaki V, Kotoula V, et al. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol, 1995,153(6) :1 947.
5Grigioni WF, D "Errico A, Fortunato C, et al. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol, 1994,7 (2) :220.
6Kanayama H,Yokota K, Kurokawa Y, et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer, 1998,82(7) :1 359.
7Still K, Robson CN, Autzen P, et al. Localization and quantification of mRNA for matrix metalloproteinase-2 ( MMP-2 ) and tissue inhibitor of metaloproteinase-2 ( TIMP-2 ) in human benign and malignant prostatic tissue. Prostate,2000,42(1):18.
8Hiragama D,Takahiro F, Satonaka K,et al.Immunohistochemical study of epidermal growth factor and transforming growth factor-β in the penetrating type of gastric cancer. Human Pathology, 1992,23(6):681-685.
9Salo T, Lyons J, Rahemtulla F,et al. Transforming growth factor-β1 up- regulates type IV collagenase expression in cultured human keratinocytes. J Bio Chem, 1991,266(18):11436 - 11441.
10Koyama T, Yashiro M, Inoue TS, et al. TGF-β1 secreted by gastric fibroblasts up - regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. International Journal of Ontology,2000,16(2):355-362.
